AUS
NZ
UK
CA
USA
IND
Highlights
- Imagion Biosystems (IBX) progresses with FDA application for its MagSense HER2 imaging agent.
- Phase 2 study aims to optimize dose and imaging protocol for improved diagnostic accuracy.
- Recent capital funding of $3 million supports the next stages of development.
Cancer detection technology continues to advance, with Imagion Biosystems (ASX:IBX) taking a significant step toward bringing its MagSense HER2 imaging agent closer to clinical use. The company has filed an application with the U.S. Food and Drug Administration (FDA) to initiate manufacturing, a necessary requirement before submitting an Investigational New Drug (IND) application, targeted for mid-2025.
Enhancing Breast Cancer Detection
MagSense HER2 is being developed to improve the assessment of axillary nodal disease in individuals diagnosed with HER2-positive breast cancer. This subtype is known for its aggressive nature, high recurrence rates, and metastasis risk, making precise imaging methods crucial for effective disease management.
Currently, ultrasound remains the standard imaging tool, but its sensitivity ranges from 49% to 87%, and specificity varies between 55% and 97%. By advancing MagSense HER2, the company aims to enhance diagnostic accuracy and provide a more reliable solution for the over 400,000 patients diagnosed with HER2+ breast cancer worldwide each year.
Milestones and Next Steps
With a production schedule now outlined by its contract manufacturer, Imagion Biosystems anticipates completing key tasks leading up to the IND application submission. Manufacturing is expected to commence in mid-April, with completion anticipated in June. The IND filing is projected to follow 30 to 60 days after production concludes.
A significant milestone has already been reached with the successful completion of a Phase 1 study, which evaluated the basic safety of the imaging agent. Phase 2 will focus on optimizing the dosage and refining imaging protocols to establish the agent’s diagnostic performance. Two previous batches were utilized in Phase 1, and a fresh batch is planned for the next phase, which will be proposed to the FDA as part of the IND application.
Financial Backing for Advancement
Funding plays a crucial role in accelerating this development. Imagion Biosystems recently secured $3 million in capital, providing the necessary resources to advance MagSense HER2 towards its next clinical milestone. With this financial support, the company is actively working toward filing the IND and preparing for the next phase of clinical trials.
As developments unfold, the progress of MagSense HER2 could pave the way for improved breast cancer diagnostics, potentially transforming the landscape of imaging technology for HER2-positive cases.
